Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma

Narita, Yoshitaka; Nagane, Motoo; Mishima, Kazuhiko; Terui, Yasuhito; Arakawa, Yoshiki; Yonezawa, Hajime; Asai, Katsunori; Fukuhara, Noriko; Sugiyama, Kazuhiko; Shinojima, Naoki; Kitagawa, Junsaku; Aoi, Arata; Nishikawa, Ryo

doi:10.1093/neuonc/noaa145

Public

Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma

Published in Neuro-Oncology • Jun 16, 2020

Authors:

Yoshitaka Narita

Motoo Nagane

Kazuhiko Mishima

Abstract

BACKGROUND: The safety, tolerability, efficacy, and pharmacokinetics of tirabrutinib, a second-generation, highly selective oral Bruton's tyrosine kinase inhibitor, were evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL). METHODS: Patients with relapsed/refractory PCNS...

Subject

Medicine

Internal medicine

Neutropenia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!